Craft

Vir Biotechnology

Stock Price

$10.3

2024-02-16

Market Capitalization

$1.4 B

2024-02-16

Revenue

$86.2 M

FY, 2023

Vir Biotechnology Summary

Company Summary

Overview
Vir Biotechnology is a clinical-stage immunology company focused on finding solutions to treat and prevent serious infectious diseases. The company brings together innovations with scientific expertise and management to take on some of the most infectious diseases for which solutions are non-existent or inadequate. Vir Biotechnology seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions.
Type
Public
Status
Active
Founded
2016
HQ
San Francisco, CA, US | view all locations
Website
http://www.vir.bio/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • George Scangos

    George Scangos, President, Chief Executive Officer and Director

    • Aine Hanly

      Aine Hanly, Chief Technology Officer

      • Howard Horn

        Howard Horn, CFO

        • Antonio Lanzavecchia

          Antonio Lanzavecchia, Senior Vice President and Senior Research Fellow

          Operating MetricsView all

          Scientific Collaborations

          5

          Oct, 2019

          Drugs in Development

          5

          Oct, 2019

          Technology Platforms

          4

          Oct, 2019

          LocationsView all

          4 locations detected

          • San Francisco, CA HQ

            United States

            499 Illinois St, San Francisco

          • Cambridge, MA

            United States

            625 Massachusetts Ave #143

          • Portland, OR

            United States

            4640 SW Macadam Ave #200B

          • Bellinzona, TI

            Switzerland

            Via dei Gaggini 3

          Vir Biotechnology Financials

          Summary Financials

          Revenue (FY, 2023)
          $86.2M
          Gross profit (FY, 2023)
          $83.4M
          Net income (FY, 2023)
          ($615.1M)
          Cash (Q3, 2023)
          $452.1M
          EBIT (FY, 2023)
          ($684.3M)
          Enterprise value
          $1.1B

          Footer menu